X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will accelerate the clinical development of PRAX-628, a next-generation, functionally selective small molecule targeting the hyperexcitable state of sodium-channels in the brain, under development for the treatment of epilepsy.
Lead Product(s): PRAX-628
Therapeutic Area: Neurology Product Name: PRAX-628
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Piper Sandler
Deal Size: $200.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 28, 2024
Details:
The net proceeds will accelerate the clinical development of PRAX-628, a next-generation, functionally selective small molecule targeting the hyperexcitable state of sodium-channels in the brain, under development for the treatment of epilepsy.
Lead Product(s): PRAX-628
Therapeutic Area: Neurology Product Name: PRAX-628
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Piper Sandler
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering March 27, 2024
Details:
PRAX-628 is a next-generation, functionally selective small molecule targeting the hyperexcitable state of sodium-channels in the brain that is currently being developed as a once daily, oral treatment for adult focal onset epilepsy.
Lead Product(s): PRAX-628
Therapeutic Area: Neurology Product Name: PRAX-628
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Details:
The net proceeds will be used to complete the development of PRAX-944 (ulixacaltamide) in two Phase 3 studies for essential tremor and to continue clinical development of PRAX-628, PRAX-562 and PRAX-222 for various epilepsies.
Lead Product(s): Ulixacaltamide
Therapeutic Area: Neurology Product Name: PRAX-944
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Piper Sandler
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 11, 2024
Details:
The net proceeds will be used to complete the development of PRAX-944 (ulixacaltamide) in two Phase 3 studies for essential tremor and to continue clinical development of PRAX-628, PRAX-562 and PRAX-222 for various epilepsies.
Lead Product(s): Ulixacaltamide
Therapeutic Area: Neurology Product Name: PRAX-944
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Piper Sandler
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering January 10, 2024
Details:
Under the agreement, Tenacia will develop and commercialize PRAX-944 (ulixacaltamide), a differentiated and highly selective small molecule inhibitor of T-type calcium channels, for the treatment of essential tremor in Greater China.
Lead Product(s): Ulixacaltamide
Therapeutic Area: Neurology Product Name: PRAX-944
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Tenacia Biotechnology
Deal Size: $279.0 million Upfront Cash: $15.0 million
Deal Type: Licensing Agreement January 05, 2024
Details:
PRAX-222 (elsunersen) is an antisense oligonucleotide (ASO) designed to selectively decrease SCN2A gene expression. It is under development for treatment of SCN2A gain of function developmental epilepsies.
Lead Product(s): Elsunersen
Therapeutic Area: Rare Diseases and Disorders Product Name: PRAX-222
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2023
Details:
PRAX-944 (ulixacaltamide) is a differentiated and highly selective small molecule inhibitor of T-type calcium channels designed to block abnormal neuronal burst firing in the Cerebello-Thalamo-Cortical circuit correlated with tremor activity.
Lead Product(s): Ulixacaltamide
Therapeutic Area: Neurology Product Name: PRAX-944
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2023
Details:
PRAX-628 is a next-generation, functionally selective small molecule targeting the hyperexcitable state of sodium-channels in the brain that is currently being developed as a once daily, oral treatment for adult focal onset epilepsy.
Lead Product(s): PRAX-628
Therapeutic Area: Neurology Product Name: PRAX-628
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 07, 2023
Details:
The net proceeds will advance the development of PRAX-944 (ulixacaltamide), a novel selective T-type calcium channel blocker, in two Phase 3 studies for essential tremor and to continue clinical development of PRAX-562, PRAX-222 and PRAX-628 for various epilepsies.
Lead Product(s): Ulixacaltamide
Therapeutic Area: Neurology Product Name: PRAX-944
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Piper Sandler
Deal Size: $63.3 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 22, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
